Targeted protein degradation represents an area of great interest, potentially offering
improvements with respect to dosing, side effects, drug resistance, and reaching …

Mass spectrometry-based proteomics profiling is a discovery tool that enables researchers
to understand the mechanisms of action of drug candidates. When applied to proteolysis …

Targeted protein degradation (TPD) is a recent strategy, utilizing the cell's proteostasis
machinery to deplete specific proteins. This represents a paradigm shift in early drug …

Targeted protein degradation has exploded over the past several years due to preclinical
and early clinical therapeutic success of numerous compounds, and the emergence of new …

Chemical proteomics focuses on the drug–target–phenotype relationship for target
deconvolution and elucidation of the mechanism of action—key and bottleneck in drug …

Small molecules continue to dominate drug discovery because of their ease of use, lower
cost of manufacturing, and access to intracellular targets. However, despite these …

Targeted protein degradation is a broad and expanding field aimed at the modulation of
protein homeostasis. A focus of this field has been directed toward molecules that hijack the …

Targeted protein degraders are heterobifunctional small molecules that link a target ligand
or bait to an E3-ligase binder via a chemical spacer. Upon entering the cell, these ligands …

Protein–protein interactions (PPIs) govern all biological processes. Some small molecules
modulate PPIs through induced protein proximity. In particular, molecular glue degraders …

Targeted protein degradation (TPD) is a new pharmacology based on small-molecule
degraders that induce proximity between a protein of interest (POI) and an E3 ubiquitin …